Abstract:In accordance with the structural characteristics of thiazolidinedione drugs and highly bioactive tyrosine derivatives, we tentatively designed the c-phenylglycine derivatives TM1 and TM2 based on basic principles of drug design and then synthesized them. The in vitro screening of peroxisome proliferator-activated receptor gamma (PPAR gamma) activated activity, alpha-glucosidase inhibitory and dipeptidyl peptidase-4 inhibitory activities showed that the novel molecule M5 had efficient PPAR response element (PPRE) activated activity (PPRE relative activity 105.04% at 10 mu g.mL(-1) compared with the positive control pioglitazone, with 100% activity). Therefore, M5 was selected as the hit compound from which the TM3 and TM4 series of compounds were further designed and synthesized. Based on the PPRE relative activities of TM3 and TM4, we discovered another new molecule, TM4h, which had the strongest PPRE relative activity (120.42% at 10 mu g.mL(-1)). In addition, the concentration-dependent activity of the highly active compounds was determined by assaying their half-maximal effective concentration (EC50) values. The molecular physical parameter calculation and the molecular toxicity prediction were used to theoretically evaluate the lead-likeness and safety of the active compounds. In conclusion, we identified a potential PPAR gamma lead molecule and developed a tangible strategy for antidiabetic drug development.

Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists

Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists

Design, Synthesis, and Antidiabetic Activity of 4-Phenoxynicotinamide and 4-Phenoxypyrimidine-5-carboxamide Derivatives As Potent and Orally Efficacious TGR5 Agonists.

Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists.

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Design and Biological Evaluation of Tetrahydropyridine Derivatives As Novel Human GPR119 Agonists

Design, Synthesis, and Biological Evaluation of Covalently Mucoadhesive Derivatives as Nonsystemic Intestine-Targeted TGR5 Agonists

Design, synthesis and biological evaluation of novel oxazole derivatives as potential hypoglycemic agents

4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists.

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5H88Y Mutant Mice

Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.

Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.

Design, Synthesis and Biological Evaluation of GY3-based Derivatives for Anti-Type 2 Diabetes Activity.

Design, Sythesis And Evaluation Of A Series Of 3-Or 4-Alkoxy Substituted Phenoxy Derivatives As Ppars Agonists

Design, Synthesis, and Evaluation of Novel L-Phenylglycine Derivatives As Potential PPARγ Lead Compounds

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes.

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists